The aim of this study was to evaluate the prognostic value of interleukin-6 (IL-6) for myocardial infarction (MI) an mortality in a population with stable coronary artery disease (CAD) during a mean period of 6.3 years. IL-6 is a mayor proinflammatory cytokine of acute phase response; elevated levels are associated with worse prognosis in unstable angina and after MI. However, data regarding its long-term prognostic value in stable CAD are limited and controversial. A nested case-control study design was used. Of 3.090 patients with stable CAD, 129 with an adequate blood sample for IL-6 and who reaches the end-points (MI or sudden death) were randomly selected. Each case was 1:1 matched with 129 control (alive at the end of the study and free of cardiovascular events) according to age, gender, and treatment. Of the 129 cases, 113 had a Ml as the initial event, and for the other 16, the initial event was sudden death. There were 8 patients who first had a MI and later died suddenly. IL-6 was significantly higher in cases (2.34 pg/ml) than in controls (1.65 pg/ml) (p=0.0004). IL-6 was significantly correlated with C-reactive protein (r=0.2, p=0.002); a borderline significance was also found for fibrinogen (r=0.11, p=0.07). Each increase of 1 pg/ml in IL-6 was associated with a 1.70 (range 1.23 to 2.45) increased relative odds of subsequent MI or sudden death. Events rate per 1.000 patients-year for the 5 quintiles of IL-6 were 72.26, 89.61, 79.76, 142.53, and 181.08, respectively (p<0.0001). A significantly higher risk in the upper quintile was found (odds ratio, 3.44; 95% confidence interval 1.57 to 8.13). In conclusion, elevated IL-6 levels are strongly associated with future cardiac events and mortality in a population with stable CAD during a long-term follow-up.
|Translated title of the contribution||Increase of risk factors in coronary events in stable chronic coronary heart disease related with interleukin-6 levels|
|Number of pages||8|
|Journal||Prensa Medica Argentina|
|State||Published - Mar 2007|